Duloxetine hydrochloride + placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful
Conditions
Diabetic Neuropathy, Painful
Trial Timeline
Oct 1, 2002 → Mar 1, 2005
NCT ID
NCT00058968About Duloxetine hydrochloride + placebo
Duloxetine hydrochloride + placebo is a phase 3 stage product being developed by Eli Lilly for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT00058968. Target conditions include Diabetic Neuropathy, Painful.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Neuropathy, Painful were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00673452 | Approved | Completed |
| NCT00536471 | Approved | Completed |
| NCT00422162 | Approved | Completed |
| NCT00408993 | Phase 3 | Completed |
| NCT00406848 | Approved | Completed |
| NCT00244296 | Approved | Completed |
| NCT00191919 | Phase 3 | Completed |
| NCT00122863 | Phase 3 | Completed |
| NCT00122824 | Phase 3 | Completed |
| NCT00190996 | Phase 3 | Completed |
| NCT00058968 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful